Case guide

Had a Tumor After Depo-Provera? What to Ask Your Doctor

Diagnosed with a tumor after using the shot? Contact your care team about the medicine and next steps.

See If You Qualify

Free · No obligation · About 2 minutes

Updated Oct 4, 202616 sources

This may apply to you if

  • Have your shot name and dates ready for a lawyer to review.
  • Have the report that names your meningioma, a tumor in tissue around the brain.
  • If you already have a lawyer, ask whether your claim is eligible for the reported program.

What the public record says

These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.

M. Casey Rodgers · U.S. District Court, Northern District of Florida · United States District Judge

Finding: The August 10, 2026 order describes an agreement for many existing federal claims and separate court procedures for continuing litigation. Ask a lawyer which track applies to you.

Case Management Order No. 14 (opens in a new tab) · Aug 10, 2026 · Checked Oct 3, 2026

Noémie Roland · EPI-PHARE, French National Agency for Medicines and Health Products Safety and French National Health Insurance · First-listed study author

Finding: The 2024 BMJ study found an association between injectable medroxyprogesterone use and meningioma surgery in French health records. A small exposed group and observational design limit what it can show about an individual.

Use of progestogens and the risk of intracranial meningioma: national case-control study (opens in a new tab) · Mar 27, 2024 · Checked Oct 3, 2026

The evidence and its limits

EPI-PHARE · BMJ · 2024

French health-record study of hormone medicines and meningioma surgery

Design:
Case-control
Participants:
108,366 women: 18,061 surgery cases and 90,305 matched controls
Finding:
Injectable medroxyprogesterone acetate use was associated with higher odds of surgery for meningioma; the excess was linked to prolonged use.
Main limitation
Observational French data; only nine exposed cases and eleven exposed controls for this injection. The study does not prove that the shot caused any one person’s tumor or define who qualifies for a claim.

Read the source: French health-record study of hormone medicines and meningioma surgery (opens in a new tab) · Checked Oct 3, 2026

The short answer

Who should help me plan the next step?
Contact the clinician who prescribes the shot and the team treating the tumor. Tell each team about the diagnosis and all medicines you use. Ask them to make a clear plan together. [3]
Which facts should I take to that visit?
Bring the diagnosis and scan reports you have. Include your shot dates and a current medicine list. Ask which missing reports the team needs before advising you. [4]
Does one study identify the best alternative for me?
No. It studies links in health records. It does not choose a medicine for someone who already has a tumor. [9]
How do I get a copy of the diagnosis record?
Ask the treating provider how to request your own records. Specify the reports and dates you need. Keep the request and any reply. [6]

What rules a case out

Not covered by this case

  • This page does not pick a birth-control method or tumor treatment.
  • An association in a study does not prove another medicine is right for you.
  • A lawsuit program is not a medical care plan.

The process

What happens next

  1. 01

    You answer a few questions

    About two minutes. Nothing is sent until you agree on the last step and press submit.

  2. 02

    A lawyer looks at it

    A lawyer at the firm reads your answers and checks them against the current case criteria.

  3. 03

    The firm decides and gets in touch

    If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.

Diagnosed with a tumor after using the shot? Contact your care team about the medicine and next steps. Your care plan and claim review are separate.

Who should help me plan the next step?

Contact the clinician who prescribes the shot and the team treating the tumor. Tell each team about the diagnosis and all medicines you use. Ask them to make a clear plan together.

The FDA label directs clinicians to stop this medicine if a meningioma is diagnosed. That is a clinical instruction to discuss with your treating team. A legal intake cannot replace that conversation.

Which facts should I take to that visit?

Bring the diagnosis and scan reports you have. Include your shot dates and a current medicine list. Ask which missing reports the team needs before advising you.

Meningiomas arise in protective tissue around the brain or spine. The NCI describes different grades. Ask which type and grade your own report identifies; the word tumor alone does not tell you that.

Keep questions about the medicine separate from questions about the tumor. Ask who will explain each part of the plan and whom to contact if the instructions are unclear.

Does one study identify the best alternative for me?

No. It studies links in health records. It does not choose a medicine for someone who already has a tumor.

The French analysis used meningioma surgery cases and matched controls. A different result for another hormone product in that research is not a personal safety guarantee. Your clinician needs your health history and reason for using the shot.

How do I get a copy of the diagnosis record?

Ask the treating provider how to request your own records. Specify the reports and dates you need. Keep the request and any reply.

Federal rules generally permit access to covered records, subject to exceptions. A provider may require a written request. Those access rules do not mean a claim service has permission to collect your records without the proper process.

Can I discuss a claim without changing my care plan?

Ask a lawyer to check the shot and tumor records. Your care team should handle treatment. If you have a lawyer, ask what legal steps remain.

The court’s settlement program and continuing litigation have different routes. Neither gives this page authority to decide your care. A program notice is not your personal offer or proof a new claim will be accepted.

Before you agree to legal work, ask about the firm, fees, expenses and records authorization. A fee based on the outcome still needs clear terms; the cited ABA rule is a model, not a promise about a particular firm.

Scientific evidence for this case

Find out where you stand.

The review is free and private. Asking for it doesn’t commit you to anything.

Register your interest

Questions about this guide

Is the Mirena IUD safe after a meningioma diagnosis?

It depends. Ask your treating clinician about symptoms, testing, or medication changes. The FDA label says to monitor for signs and symptoms of meningioma and to discontinue Depo-Provera CI if a meningioma is diagnosed. A claim page cannot diagnose you or decide your medical care.

Source: FDA Depo-Provera CI label, revised December 2025 · as of Oct 7, 2026

How quickly should I stop Depo-Provera if diagnosed with a meningioma?

Ask your treating clinician about symptoms, testing, or medication changes. The FDA label says to monitor for signs and symptoms of meningioma and to discontinue Depo-Provera CI if a meningioma is diagnosed. A claim page cannot diagnose you or decide your medical care.

Source: FDA Depo-Provera CI label, revised December 2025 · as of Oct 7, 2026

Will stopping Depo-Provera cause withdrawal symptoms?

It depends. Ask your treating clinician about symptoms, testing, or medication changes. The FDA label says to monitor for signs and symptoms of meningioma and to discontinue Depo-Provera CI if a meningioma is diagnosed. A claim page cannot diagnose you or decide your medical care.

Source: FDA Depo-Provera CI label, revised December 2025 · as of Oct 7, 2026

Sources

  1. Court order 14: settlement and ongoing casesCourt order 14: settlement and ongoing cases · court
  2. JPML pending cases report, October 1, 2026JPML pending cases report, October 1, 2026 · court
  3. FDA Depo-Provera CI label, December 2025FDA Depo-Provera CI label, December 2025 · regulator
  4. National Cancer Institute: meningiomaNational Cancer Institute: meningioma · regulator
  5. ABA Model Rule 1.5: feesABA Model Rule 1.5: fees
  6. Medical record access: 45 CFR 164.524Medical record access: 45 CFR 164.524 · regulator
  7. SDNY court guide: filing time limitsSDNY court guide: filing time limits · court
  8. Court common-benefit fee order 2Court common-benefit fee order 2 · court
  9. BMJ 2024 original author abstract via PubMedBMJ 2024 original author abstract via PubMed · study
  10. Medroxyprogesterone Acetate and Meningioma: A Global IssueFrontiers in Global Womens Health · 2025 · study
  11. Use of High-Dose Medroxyprogesterone Acetate and Risk of Intracranial MeningiomaThe BMJ · 2024 · study
  12. The Association between Medroxyprogesterone Acetate Exposure and MeningiomaCancers · 2024 · study
  13. Pfizer Reaches Agreement in Principle to Resolve Federal Depo-Provera MDLlaw360.com · Jun 15, 2026 · court
  14. JAMA Network Open Study Reports 4.5x Meningioma Risk with Medroxyprogesteronepubmed.ncbi.nlm.nih.gov · Jul 1, 2026 · study
  15. On June 15, 2026, MDL 3140 (N.D. Fla.) Leadership Counsel announced a settlement with the Pfizer defendants of a majority of the claims in the MDL and New York state court over Depo-Provera meningioma claims (Case Management Order No. 12, filed July 27, 2026). Financial terms NOT disclosed; eligibility and compensation amounts not released; deal pending finalization at the time (Case Management Order No. 14, filed Aug. 10, 2026, later described a settlement agreement dated July 22, 2026 and states no compensation amounts). The JPML reported 5,830 actions pending in MDL 3140 on July 1, 2026 and 6,412 on October 1, 2026.flnd.uscourts.gov · Jun 15, 2026 · court
  16. Settlement in principle announced; docket had grown +1,739 filings (+46%) in the single preceding month — the leading-indicator pattern.jpml.uscourts.gov · Jun 15, 2026 · court

Checked against 14 primary sources by People's Justice editors · Updated

How we make money

People's Justice research team · Updated Oct 4, 2026